Home> Focus

Focus

 

Big Data (analytics): to enable better and faster treatment for Patients with Hematologic Malignancies (HMs)


The HARMONY Alliance uses big data technologies to improve the treatment of seven hematologic malignancies. These are cancers that affect the blood and lymphatic system. In recent decades, diagnosis and treatment of these diseases has substantially improved, but many remain incurable. Taken together, hematologic malignancies rank third after lung cancer and colorectal cancer in terms of age-adjusted mortality in Europe. In addition, they strongly contribute to loss of productivity.


View the HARMONY Research Projects > | Learn more about the HARMONY Big Data Platform >


The key outstanding questions in this field can only be answered by studying large numbers of patients. Therefore, the HARMONY Alliance will generate a harmonized European clinical data platform, assembling data from thousands of European patients. This will enable the HARMONY researchers to characterize the molecular landscape of the seven malignancies, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. Ultimately, this should result in tools to rapidly select the most promising treatment strategy for a particular patient (i.e. personalized medicine).

In parallel, the HARMONY Alliance is developing core outcome sets for hematologic malignancies. These may assist researchers in selecting outcomes for future trials, thereby promoting harmonization of HM studies and improving clinical management of the diseases. HARMONY aims to meet the needs of patients with hematologic malignancies by increasing treatment efficacy, decreasing adverse effects, prolonging survival, and increasing patients’ quality of life. 


HARMONY focuses on 7 Hematological Malignancies:


The HARMONY Alliance is a public-private Partnership for Big Data in Hematology, established in January 2017. We currently have 53 Partners and 41 Associated Members from 17 European countries, including 9 pharmaceutical companies and 7 European Patient Umbrella Organizations. Read more >